Blueprint Medicines
Cambridge, US · 4 known investors
Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes. It markets approved therapies internationally and runs patient access programs across multiple countries.
BiotechHealthtech
Founders & leadership
AB
Alexis BorisyNamed on SEC filing
DL
Daniel LynchNamed on SEC filing
NL
Nick LydonNamed on SEC filing
DS
David SchenkeinNamed on SEC filing
SK
Stephen KnightNamed on SEC filing
TS
Thilo SchroederNamed on SEC filing
CS
Christoph S. LengauerNamed on SEC filing
CB
Christine BellonNamed on SEC filing
KK
Kyle KuvalankaNamed on SEC filing
Investors · 4
Reported raises · per SEC filings
Form D private placements$73.2M disclosed across 2 rounds · 2014
▶$50MraisedNov 2014 · 29 investors · BiotechnologyRule 506(b)
▶$50MraisedNov 2014 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexis BorisyDirector
- Nicholas LydonDirector
- Jeffrey W. AlbersExecutive Officer, Director
- Kyle KuvalankaExecutive Officer
- Stephen KnightDirector
- Thilo SchroederDirector
- Christoph S. LengauerExecutive Officer
- David SchenkeinDirector
- Daniel LynchDirector
- Christine BellonExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.2MraisedJan 2014 · 10 investors · BiotechnologyRule 506(b)
▶$23.2MraisedJan 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexis BorisyExecutive Officer, Director
- Daniel LynchDirector
- Nick LydonDirector
- David SchenkeinDirector
- Stephen KnightDirector
- Thilo SchroederDirector
- Christoph S. LengauerExecutive Officer
- Christine BellonExecutive Officer
- Kyle KuvalankaExecutive Officer
- Offering amount
- $25.1M
- Amount sold
- $23.2M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Blueprint Medicines went on to found or lead other companies.
Frequently asked questions
- What does Blueprint Medicines do?
- Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes. It markets approved therapies internationally and runs patient access programs across multiple countries.
- Who are Blueprint Medicines's investors?
- Blueprint Medicines's investors include F-Prime Capital Partners, Foresite Capital, Nextech Invest, RA Capital.
- How much funding has Blueprint Medicines raised?
- Blueprint Medicines has disclosed $73.2M raised across 2 rounds.
- Where is Blueprint Medicines headquartered?
- Blueprint Medicines is headquartered in Cambridge, US.